Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T cell proliferative response

Journal of Infectious Diseases

Volumn 179, Issue 2, 1999, Pages 337-344

  Ratto Kim, Silvia ^d   Sitz, Karl V ^e   Garner, Robin P ^e   Kim, Jerome H ^e   Davis, Charles ^a   Aronson, Naomi ^e   Ruiz, Nancy ^b   Tencer, Kathleen ^c   Redfield, Robert R ^e   Birx, Deborah L ^e  

^a UNIVERSITY OF MARYLAND   (United States)

^b DUPONT COMPANY   (United States)

^c PFIZER INC   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CONCANAVALIN A; DIPHTHERIA TOXOID; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; TETANUS TOXOID;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; AIDS VACCINES; CRYOPRESERVATION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HUMANS; IMMUNIZATION; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MITOGENS; T-LYMPHOCYTE SUBSETS; VACCINES, SYNTHETIC;

EID: 0000333223     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314587     Document Type: Article

References (21)

1. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-23.
2. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med 1986;315:393-4.
3. Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE. CD4' lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci USA 1989;86:1993-7.
4. Krowka JF, Stites DP, Jain S, et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989;83:1198-203.
5. Shearer GM, Clerici M. Early T-helper cell defects in HIV infection [editorial]. AIDS 1991;5:245-53.
6. Bentin J, Tsoukas CD, McCutchan JA, Spector SA, Richman DD, Vaughan JH. Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus. J Clin Immunol 1989;9:159-68.
7. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield RR. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr 1991;4:188-96.
8. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;313:79-84.
9. Shearer GM, Bernstein DC, Tung KSK, et al. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986;137:2514-21.
10. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-84.
11. Wahren B, Bratt G, Persson C, et al. Improved cell-mediated immune responses in HIV-1 infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994;7:220-9.
12. Valentine FT, Kundu S, Haslett PA, et al. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≥400/mm'CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996;173:1336-46.
13. Levine AM, Groshen S, Allen J, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:351-64.
14. Gorse GJ, Belshe RB, Newman FK, Frey SE. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. Vaccine 1992;10:383-8.
15. Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991;163:448-53.
16. Kovacs JA, Vasudevachari MB, Easter M, et al. Induction of humoral and cell-mediated anti human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-28.
17. Tacket CO, Baqar S, Munoz C, Murphy JR. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160. AIDS Res Hum Retroviruses 1990;6:535-42.
18. Torseth JW, Berman PW, Merigan TC. Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. AIDS Res Hum Retroviruses 1988;4:23-30.
19. Pontesilli O, Carlesimo M, Varani AR, Ferrara R, D'Offizi G, Aiuti F. In vitro lymphocyte proliferative response to HIV-1 p24 is associated with a lack of CD4' cell decline [letter]. AIDS Res Hum Retroviruses 1994;10:113-4.
20. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37.
21. Stanley S, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.